Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

The Lancet Neurology

Volumn 9, Issue 7, 2010, Pages 740-750

  Polman, Chris H ^a   Bertolotto, Antonio ^b   Deisenhammer, Florian ^c   Giovannoni, Gavin ^d   Hartung, Hans Peter ^e   Hemmer, Bernhard ^f   Killestein, Joep ^a   McFarland, Henry F ^g   Oger, Joel ^h   Pachner, Andrew R ⁱ   Petkau, John ^j   Reder, Anthony T ^k   Reingold, Stephen C ^l   Schellekens, Huub ^m   Sørensen, Per Soelberg ⁿ  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Multiple Sclerosis Regional Referral Centre   (Italy)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k UNIVERSITY OF CHICAGO   (United States)

^l Scientific and Clinical Review Associates LLC   (United States)

^m UTRECHT UNIVERSITY   (Netherlands)

ⁿ Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; NEUTRALIZING ANTIBODY;

ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; GENETIC PREDISPOSITION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 77953454473     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70103-4     Document Type: Note

References (77)

1. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 23 (2009) 379-396
2. Farrell R.A., and Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler 13 (2007) 567-577
3. Goodin D.S., Frohman E.M., Hurwitz B., et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68 (2007) 977-984
4. Malucchi S., Sala A., Gilli F., et al. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology 62 (2004) 2031-2037
5. Ross C., Clemmesen K.M., Svenson M., et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48 (2000) 706-712
6. Rudick R.A., and Polman C.H. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 8 (2009) 545-559
7. Sorensen P.S., Ross C., Clemmesen K.M., et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
8. Sorensen P.S., Deisenhammer F., Duda P., et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12 (2005) 817-827
9. Bertolotto A., Sala A., Malucchi S., et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 75 (2004) 1294-1299
10. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., and Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52 (1999) 1239-1243
11. Farrell R., Kapoor R., Leary S., et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler 14 (2008) 212-218
12. Kappos L., Clanet M., Sandberg-Wollheim M., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65 (2005) 40-47
13. van der Voort L.F., Visser A., Knol D.L., Oudejans C.B., Polman C.H., and Killestein J. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol 16 (2009) 1049-1052
14. Farrell R.A., Worthington V., Creeke P., and Giovannoni G. What do we do with positive neutralising antibody tests in subjects with MS?. Mult Scler 15 9 suppl (2009) S242
15. Hesse D., and Sorensen P.S. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 14 (2007) 850-859
16. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., and Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33-39
17. Sorensen P.S., Koch-Henriksen N., and Bendtzen K. Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis?. Mult Scler 13 (2007) 616-621
18. IFNβ Multiple Sclerosis Study Group, and University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47 (1996) 889-894
19. Francis G.S., Rice G.P., and Alsop J.C. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65 (2005) 48-55
20. Frank J.A., Richert N., Bash C., et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 62 (2004) 719-725
21. Perini P., Calabrese M., Biasi G., and Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 251 (2004) 305-309
22. Boz C., Oger J., Gibbs E., and Grossberg S.E. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 13 (2007) 1127-1137
23. Malucchi S., Gilli F., Caldano M., et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70 (2008) 1119-1127
24. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
25. Ebers G.C., and PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
26. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
27. Clanet M., Radue E.W., Kappos L., et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59 (2002) 1507-1517
28. Petkau A.J., White R.A., Ebers G.C., et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 10 (2004) 126-138
29. Polman C., Kappos L., White R., et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60 (2003) 37-43
30. Koch-Henriksen N., Sorensen P.S., Bendtzen K., and Flachs E.M. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Mult Scler 15 (2009) 601-605
31. Freedman M.S., Polman C., Edan G., et al. The impact of neutralizing antibodies within 5 years of treatment with interferon beta-1b initiated at the first event suggestive of multiple sclerosis. Neurology 72 suppl 3 (2009) A197-A198
32. Goodin D.S., O'Connor P.W., Hartung H.P., et al. Neutralizing antibodies during treatment with interferon beta-1b in 1745 patients with relapsing-remitting multiple sclerosis. Neurology 72 suppl 3 (2009) A317-A318
33. Kappos L., Freedman M.S., Polman C.H., et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8 (2009) 987-997
34. Pachner A.R., Cadavid D., Wolansky L., and Skurnick J. Effect of anti-IFNβ antibodies on MRI lesions of MS patients in the BECOME study. Neurology 73 (2009) 1485-1492
35. Hoffmann S., Cepok S., Grummel V., et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 83 (2008) 219-227
36. Gneiss C., Reindl M., Lutterotti A., et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 10 (2004) 507-510
37. Grossberg S.E., Kawade Y., Kohase M., and Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21 (2001) 743-755
38. Grossberg S.E., Kawade Y., Kohase M., Yokoyama H., and Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21 (2001) 729-742
39. Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titre. J Interferon Res 1 (1980) 61-70
40. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., and Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48 (2000) 95-100
41. Gneiss C., Tripp P., Reichartseder F., et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 12 (2006) 731-737
42. Herndon R.M., Rudick R.A., Munschauer III F.E., et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 11 (2005) 409-419
43. Bertolotto A., Gilli F., Sala A., et al. Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256 (2001) 141-152
44. Reder A.T., Velichko S., Yamaguchi K.D., et al. IFN-β1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 28 (2008) 317-331
45. Pachner A.R., Dail D., Pak E., and Narayan K. The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect of anti-IFNβ antibodies. J Neuroimmunol 166 (2005) 180-188
46. Bertolotto A., Gilli F., Sala A., et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60 (2003) 634-639
47. Sominanda A., Hillert J., and Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 79 (2008) 57-62
48. Sorensen P.S., Tscherning T., Mathiesen H.K., et al. Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS. Neurology 67 (2006) 1681-1683
49. Gilli F., Marnetto F., Stefanuto G., et al. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol Diagn 8 (2004) 185-194
50. Gilli F., Bertolotto A., Sala A., et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 127 (2004) 259-268
51. Pachner A.R., Narayan K., and Pak E. Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patients. Neurology 66 (2006) 444-446
52. Gilli F., Marnetto F., Caldano M., et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 12 (2006) 47-57
53. Santos R., Weinstock-Guttman B., Tamaño-Blanco M., et al. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 176 (2006) 125-133
54. Scagnolari C., Duda P., Bagnato F., et al. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol 254 (2007) 597-604
55. Hoffmann L.A., Krumbholz M., Faber H., et al. Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies. Neurology 68 (2007) 958-959
56. Capra R., Sottini A., Cordioli C., et al. IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol 189 (2007) 102-110
57. van der Voort L.F., Kok A., Visser A., et al. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler 15 (2009) 212-218
58. Aarskog N.K., Marøy T., Myhr K.M., and Vedeler C.A. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol 212 (2009) 148-150
59. Hesse D., Sellebjerg F., and Sorensen P.S. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 73 (2009) 372-377
60. Pachner A.R., Warth J.D., Pace A., and Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology 73 (2009) 1493-1500
61. Gilli F., Marnetto F., Caldano M., et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158 (2005) 195-203
62. Sominanda A., Hillert J., and Fogdell-Hahn A. Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent. Eur J Neurol 16 (2009) 21-26
63. Giovannoni G., Lai M., Kidd D., et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 120 (1997) 1-13
64. Krumbholz M., Faber H., Steinmeyer F., et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131 (2008) 1455-1463
65. Durelli L., Barbero P., Bergui M., et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 79 (2008) 646-651
66. Comabella M., Lunemann J.D., Rio J., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132 (2009) 3353-3365
67. van Baarsen L.G., Vosslamber S., Tijssen M., et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3 (2008) e1927
68. Bertolotto A., Malucchi S., Sala A., et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73 (2002) 148-153
69. Sominanda A., Rot U., Suoniemi M., Deisenhammer F., Hillert J., and Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13 (2007) 208-214
70. Giovannoni G., Barbarash O., Casset-Semanaz F., et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 15 (2009) 219-228
71. Phillips J.T., Rice G., Frohman E., et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 26 (2004) 511-521
72. Reingold S.C., Steiner J.P., Polman C.H., et al. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology 73 (2009) 552-559
73. Gupta S., Indelicato S.R., Jethwa V., et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 321 (2007) 1-18
74. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289 (2004) 1-16
75. European Medicines Agency. Beta-interferons and neutralising antibodies (in multiple sclerosis). BWP report to the CHMP. Biologics working party meeting, 11-13 February 2008 [EMEA/CHMP/BWP/580136/2007]. http://www.ema.europa.eu/pdfs/human/bwp/58013607en.pdf (accessed April 12, 2010).
76. Gibbs E., Gong E., Smith P., Grossberg S., and Oger J. The mRNA induction of myxovirus resistance protein A (MxA) in one interferon beta-treated (IFNβ) multiple sclerosis (MS) patient presenting with neutralizing antibodies. Can J Neurol Sci 31 suppl 1 (2006) S35
77. Antonelli G., Simeoni E., Bagnato F., et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 168 (1999) 131-136